Terug
Dagbereik
€ 33,02
€ 38,00
52-Weeksbereik
€ 15,49
€ 38,06
Volume
200
50D / 200D Gem.
€ 34,65
/
€ 29,90
Vorige Slotkoers
€ 33,02
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 2,9 | 0,3 |
| P/B | 1,5 | 2,9 |
| ROE % | 71,4 | 3,7 |
| Net Margin % | 51,1 | 3,8 |
| Rev Growth 5Y % | 204,7 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 0,00
€ 0,00 – € 0,00
|
5,9 B | 0 |
| FY2029 |
€ 25,26
€ 15,23 – € 38,31
|
4,5 B | 1 |
| FY2028 |
€ 6,68
€ 4,03 – € 10,14
|
2,4 B | 1 |
Belangrijkste Punten
Revenue grew 204,66% annually over 5 years — strong growth
ROE of 71,38% indicates high profitability
Net margin of 51,14% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Negative free cash flow of 0,0
P/E of 2,87 — trading at a low valuation
Groei
Revenue Growth (5Y)
204,66%
Revenue (1Y)674,85%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
71,38%
ROIC50,31%
Net Margin51,14%
Op. Margin68,44%
Veiligheid
Debt / Equity
0,04
Current Ratio4,78
Interest Coverage36,10
Waardering
P/E Ratio
2,87
P/B Ratio1,49
EV/EBITDA1,44
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 674,85% | Revenue Growth (3Y) | 79,92% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | 110,91% |
| Revenue Growth (5Y) | 204,66% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,99B | Net Income (TTM) | 1,02B |
| ROE | 71,38% | ROA | 39,70% |
| Gross Margin | 97,04% | Operating Margin | 68,44% |
| Net Margin | 51,14% | Free Cash Flow (TTM) | 0,0 |
| ROIC | 50,31% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,04 | Current Ratio | 4,78 |
| Interest Coverage | 36,10 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 2,87 | P/B Ratio | 1,49 |
| P/S Ratio | 1,47 | PEG Ratio | -0,04 |
| EV/EBITDA | 1,44 | Dividend Yield | 0,00% |
| Market Cap | 2,93B | Enterprise Value | 1,96B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,99B | 257,35M | 616,00M | 228,29M | 23,15M |
| Net Income | 1,02B | -177,08M | 229,25M | -11,18M | -119,79M |
| EPS (Diluted) | 11,52 | -2,00 | 2,59 | -0,13 | -1,36 |
| Gross Profit | 1,94B | 230,37M | 526,37M | 153,97M | -31,92M |
| Operating Income | 1,36B | -228,51M | 252,64M | -17,44M | -139,72M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,57B | 1,11B | 1,19B | 858,31M | 897,73M |
| Total Liabilities | 606,62M | 216,74M | 139,50M | 72,07M | 109,05M |
| Shareholders' Equity | 1,96B | 894,94M | 1,05B | 786,24M | 788,68M |
| Total Debt | 72,24M | 54,23M | 4,98M | 10,04M | 15,88M |
| Cash & Equivalents | 1,04B | 512,93M | 611,57M | 805,39M | 848,41M |
| Current Assets | 2,48B | 1,01B | 1,15B | 820,84M | 861,79M |
| Current Liabilities | 519,47M | 175,66M | 124,97M | 70,88M | 101,27M |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Capital Heavy Grower
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt
Value Investing (Warren Buffett)
Mar 24, 2026